These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27255951)

  • 21. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
    Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
    Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
    Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
    Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
    Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
    Chen J; Ren Q; Cai Y; Lin T; Zuo W; Wang J; Lin R; Zhu L; Wang P; Dong H; Zhao H; Huang L; Fu Y; Yang S; Tan J; Lan X; Wang S
    Biochem Biophys Res Commun; 2018 Jun; 501(1):212-219. PubMed ID: 29715459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells.
    Mieszkowska M; Piasecka D; Potemski P; Debska-Szmich S; Rychlowski M; Kordek R; Sadej R; Romanska HM
    Transl Res; 2019 May; 207():44-55. PubMed ID: 30639369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
    Samant GV; Sylvester PW
    Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
    Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
    Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
    Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
    Stern DF
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
    Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
    Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
    Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B
    Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
    Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
    Cook RS; Garrett JT; Sánchez V; Stanford JC; Young C; Chakrabarty A; Rinehart C; Zhang Y; Wu Y; Greenberger L; Horak ID; Arteaga CL
    Cancer Res; 2011 Jun; 71(11):3941-51. PubMed ID: 21482676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.